4.0 Article

Clinical and Transcriptional Response to the Long-Acting Interleukin-1 Blocker Canakinumab in Blau Syndrome-Related Uveitis

Related references

Note: Only part of the references are listed.
Review Rheumatology

Blau syndrome revisited

Carlos D. Rose et al.

CURRENT OPINION IN RHEUMATOLOGY (2011)

Article Ophthalmology

Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene

Veena Rao Raiji et al.

JOURNAL OF AAPOS (2011)

Article Pediatrics

Identification of Blau Syndrome disease signatures

KP Foley et al.

Pediatric Rheumatology (2011)

Letter Rheumatology

Interleukin-1β suppression in Blau syndrome: comment on the article by Martin et al

Junya Masumoto et al.

ARTHRITIS AND RHEUMATISM (2009)

Article Rheumatology

The NOD2 Defect in Blau Syndrome Does Not Result in Excess Interleukin-1 Activity

Tammy M. Martin et al.

ARTHRITIS AND RHEUMATISM (2009)

Article Medicine, General & Internal

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

Helen J. Lachmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Article Cell Biology

MDP-induced interleukin-1β processing requires Nod2 and CIAS1/NALP3

Qilin Pan et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2007)

Article Rheumatology

Pediatric granulomatous arthritis -: An international registry

Carlos D. Rose et al.

ARTHRITIS AND RHEUMATISM (2006)

Article Genetics & Heredity

CARD15 mutations in Blau syndrome

C Miceli-Richard et al.

NATURE GENETICS (2001)